{"id":57005,"date":"2026-02-12T22:13:39","date_gmt":"2026-02-12T14:13:39","guid":{"rendered":"https:\/\/flcube.com\/?p=57005"},"modified":"2026-02-12T22:13:40","modified_gmt":"2026-02-12T14:13:40","slug":"sanofi-invests-30-million-in-glubios-sickle-cell-tpd-programs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57005","title":{"rendered":"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs"},"content":{"rendered":"\n<p><strong>GluBio Pharmaceutical Co., Ltd.<\/strong>, a <strong>Zhejiang-based molecular glue targeted protein degradation (TPD) specialist<\/strong>, announced a <strong>USD\u202f30 million strategic equity investment<\/strong> from <strong>Sanofi<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/SNY:NASDAQ\">NASDAQ:\u202fSNY<\/a><\/strong>). The funding will <strong>advance GluBio&#8217;s two core sickle cell disease programs\u2014GLB-005 and GLB-007<\/strong>\u2014<strong>oral disease-modifying therapies<\/strong> that <strong>reactivate fetal hemoglobin<\/strong> through <strong>WIZ and ZBTB7A protein degradation<\/strong>, with <strong>Phase I trials anticipated by end-2026<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Investee<\/strong><\/td><td>GluBio Pharmaceutical Co., Ltd. (Zhejiang, China)<\/td><\/tr><tr><td><strong>Investor<\/strong><\/td><td>Sanofi S.A. (NASDAQ:\u202fSNY)<\/td><\/tr><tr><td><strong>Investment<\/strong><\/td><td><strong>USD\u202f30 million<\/strong> strategic equity<\/td><\/tr><tr><td><strong>Security Type<\/strong><\/td><td>Newly issued preferred shares<\/td><\/tr><tr><td><strong>Rights Granted<\/strong><\/td><td><strong>Right of First Negotiation (ROFN)<\/strong> for exclusive license to GLB-005 and GLB-007<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Sickle cell disease (SCD)<\/td><\/tr><tr><td><strong>Clinical Timeline<\/strong><\/td><td>Phase I initiation: <strong>End of 2026<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-pipeline-amp-mechanism\">Product Pipeline &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Target<\/th><th>Mechanism<\/th><th>Therapeutic Goal<\/th><\/tr><\/thead><tbody><tr><td><strong>GLB-005<\/strong><\/td><td><strong>WIZ protein<\/strong><\/td><td>Selective WIZ degradation<\/td><td><strong>Fetal hemoglobin (HbF) reactivation<\/strong><\/td><\/tr><tr><td><strong>GLB-007<\/strong><\/td><td><strong>WIZ + ZBTB7A proteins<\/strong><\/td><td>Dual-target degradation<\/td><td><strong>Enhanced HbF induction<\/strong> via dual repressor blockade<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biological Rationale:<\/strong> WIZ and ZBTB7A are <strong>fetal hemoglobin repressors<\/strong>; their degradation <strong>derepresses HbF genes<\/strong>, enabling <strong>functional red blood cell production<\/strong> that <strong>counteracts sickling<\/strong><\/li>\n\n\n\n<li><strong>TPD Advantage:<\/strong> <strong>Molecular glue<\/strong> enables <strong>oral, small-molecule<\/strong> administration vs. <strong>gene therapy (Casgevy, Lyfgenia)<\/strong> requiring <strong>complex manufacturing and hospitalization<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-competitive-context\">Strategic Positioning &amp; Competitive Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Market Analysis<\/th><\/tr><\/thead><tbody><tr><td><strong>Sickle Cell Disease Burden<\/strong><\/td><td><strong>&gt;100,000 patients in US<\/strong>; <strong>&gt;300,000 births annually globally<\/strong> (primarily Africa, India, Middle East); <strong>lifelong transfusion\/CRISPR therapy limited by access\/cost<\/strong><\/td><\/tr><tr><td><strong>Current Standards<\/strong><\/td><td><strong>Hydroxyurea<\/strong> (partial HbF induction, toxicity); <strong>Casgevy\/Lyfgenia<\/strong> (gene therapy, $2-3M cost, complex logistics); <strong>crizanlizumab<\/strong> (anti-P-selectin, symptom management)<\/td><\/tr><tr><td><strong>GluBio Differentiation<\/strong><\/td><td><strong>Oral, disease-modifying TPD approach<\/strong>; <strong>potentially curative mechanism<\/strong> with <strong>pharmaceutical scalability and accessibility<\/strong><\/td><\/tr><tr><td><strong>Sanofi Strategy<\/strong><\/td><td><strong>Rare disease and hematology focus<\/strong>; <strong>TPD platform bet<\/strong> complements <strong>SAR444245 (GSK3 inhibitor)<\/strong> and <strong>fitusiran (RNAi)<\/strong> in hemoglobinopathies<\/td><\/tr><tr><td><strong>China-US Bridge<\/strong><\/td><td><strong>GluBio China-based R&amp;D<\/strong> + <strong>Sanofi global commercialization<\/strong> potential via ROFN; <strong>cost-efficient development<\/strong> with <strong>Big Pharma validation<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activity<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>Sanofi equity investment; GLB-005\/007 IND-enabling studies<\/td><td>2026<\/td><\/tr><tr><td><strong>Preclinical<\/strong><\/td><td>GMP manufacturing; toxicology; biomarker validation<\/td><td>2026<\/td><\/tr><tr><td><strong>Clinical<\/strong><\/td><td><strong>Phase I initiation<\/strong> (safety, HbF induction proof-of-concept)<\/td><td><strong>End of 2026<\/strong><\/td><\/tr><tr><td><strong>Partnership<\/strong><\/td><td>Sanofi ROFN exercise decision; potential exclusive license negotiation<\/td><td>Data-dependent (2027-2028)<\/td><\/tr><tr><td><strong>Expansion<\/strong><\/td><td>Pediatric SCD studies; combination with hydroxyurea or gene therapy<\/td><td>Post-Phase I<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding GLB-005 and GLB-007 clinical development, Sanofi partnership progression, and sickle cell disease TPD market potential. Actual results may differ due to Phase I safety outcomes, HbF reactivation durability, and competitive dynamics with CRISPR gene therapies and next-generation HbF inducers.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GluBio Pharmaceutical Co., Ltd., a Zhejiang-based molecular glue targeted protein degradation (TPD) specialist, announced a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":57006,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2131,867,24,147,70],"class_list":["post-57005","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-glubio-pharmaceutical","tag-nasdaq-sny","tag-rare-orphan-disease-drugs","tag-sanofi","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GluBio Pharmaceutical Co., Ltd., a Zhejiang-based molecular glue targeted protein degradation (TPD) specialist, announced a USD\u202f30 million strategic equity investment from Sanofi (NASDAQ:\u202fSNY). The funding will advance GluBio&#039;s two core sickle cell disease programs\u2014GLB-005 and GLB-007\u2014oral disease-modifying therapies that reactivate fetal hemoglobin through WIZ and ZBTB7A protein degradation, with Phase I trials anticipated by end-2026.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57005\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs\" \/>\n<meta property=\"og:description\" content=\"GluBio Pharmaceutical Co., Ltd., a Zhejiang-based molecular glue targeted protein degradation (TPD) specialist, announced a USD\u202f30 million strategic equity investment from Sanofi (NASDAQ:\u202fSNY). The funding will advance GluBio&#039;s two core sickle cell disease programs\u2014GLB-005 and GLB-007\u2014oral disease-modifying therapies that reactivate fetal hemoglobin through WIZ and ZBTB7A protein degradation, with Phase I trials anticipated by end-2026.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57005\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T14:13:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-12T14:13:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1207.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57005#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57005\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs\",\"datePublished\":\"2026-02-12T14:13:39+00:00\",\"dateModified\":\"2026-02-12T14:13:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57005\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57005#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1207.webp\",\"keywords\":[\"GluBio Pharmaceutical\",\"NASDAQ: SNY\",\"Rare \\\/ orphan disease drugs\",\"Sanofi\",\"TPD\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57005#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57005\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57005\",\"name\":\"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57005#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57005#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1207.webp\",\"datePublished\":\"2026-02-12T14:13:39+00:00\",\"dateModified\":\"2026-02-12T14:13:40+00:00\",\"description\":\"GluBio Pharmaceutical Co., Ltd., a Zhejiang-based molecular glue targeted protein degradation (TPD) specialist, announced a USD\u202f30 million strategic equity investment from Sanofi (NASDAQ:\u202fSNY). The funding will advance GluBio's two core sickle cell disease programs\u2014GLB-005 and GLB-007\u2014oral disease-modifying therapies that reactivate fetal hemoglobin through WIZ and ZBTB7A protein degradation, with Phase I trials anticipated by end-2026.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57005#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57005\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57005#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1207.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1207.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57005#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs - Insight, China&#039;s Pharmaceutical Industry","description":"GluBio Pharmaceutical Co., Ltd., a Zhejiang-based molecular glue targeted protein degradation (TPD) specialist, announced a USD\u202f30 million strategic equity investment from Sanofi (NASDAQ:\u202fSNY). The funding will advance GluBio's two core sickle cell disease programs\u2014GLB-005 and GLB-007\u2014oral disease-modifying therapies that reactivate fetal hemoglobin through WIZ and ZBTB7A protein degradation, with Phase I trials anticipated by end-2026.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57005","og_locale":"en_US","og_type":"article","og_title":"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs","og_description":"GluBio Pharmaceutical Co., Ltd., a Zhejiang-based molecular glue targeted protein degradation (TPD) specialist, announced a USD\u202f30 million strategic equity investment from Sanofi (NASDAQ:\u202fSNY). The funding will advance GluBio's two core sickle cell disease programs\u2014GLB-005 and GLB-007\u2014oral disease-modifying therapies that reactivate fetal hemoglobin through WIZ and ZBTB7A protein degradation, with Phase I trials anticipated by end-2026.","og_url":"https:\/\/flcube.com\/?p=57005","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-12T14:13:39+00:00","article_modified_time":"2026-02-12T14:13:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1207.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57005#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57005"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs","datePublished":"2026-02-12T14:13:39+00:00","dateModified":"2026-02-12T14:13:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57005"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57005#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1207.webp","keywords":["GluBio Pharmaceutical","NASDAQ: SNY","Rare \/ orphan disease drugs","Sanofi","TPD"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57005#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57005","url":"https:\/\/flcube.com\/?p=57005","name":"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57005#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57005#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1207.webp","datePublished":"2026-02-12T14:13:39+00:00","dateModified":"2026-02-12T14:13:40+00:00","description":"GluBio Pharmaceutical Co., Ltd., a Zhejiang-based molecular glue targeted protein degradation (TPD) specialist, announced a USD\u202f30 million strategic equity investment from Sanofi (NASDAQ:\u202fSNY). The funding will advance GluBio's two core sickle cell disease programs\u2014GLB-005 and GLB-007\u2014oral disease-modifying therapies that reactivate fetal hemoglobin through WIZ and ZBTB7A protein degradation, with Phase I trials anticipated by end-2026.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57005#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57005"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57005#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1207.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1207.webp","width":1080,"height":608,"caption":"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57005#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sanofi Invests $30 Million in GluBio\u2019s Sickle Cell TPD Programs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1207.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57005"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57005\/revisions"}],"predecessor-version":[{"id":57007,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57005\/revisions\/57007"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57006"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}